Use of eltrombopag in thrombocytopenia of liver disease

doi:10.5497/wjp.v3.i4.186

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11166)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

644

WORD

409

HTML

6684

Tables (1-2)

320

Sum=8057

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1442

Download

1667

Sum=3109

Dec 9, 2014 (publication date) through Mar 2, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Pharmacol. Dec 9, 2014; 3(4): 186-192
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.186

Table 1 Mechanisms of thrombocytopenia in liver disease

In chronic liver disease

Decreased Thrombopoietin production

Splenic sequestration

Autoantibodies against platelets

Expansion of plasma volume

Bone marrow suppression (Alcohol)

In specific liver diseases

Viral or alcohol related marrow suppression

Autoimmune thrombocytopenia

Cryoglobulins

Drugs: Interferon mediated marrow suppression

Citation: Sharma V. Use of eltrombopag in thrombocytopenia of liver disease. World J Pharmacol 2014; 3(4): 186-192
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/186.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.186